Medical devices, healthcare technology and the business of care
DEVICE CATEGORY · PQP

Next Generation Sequencing Oncology Panel, Somatic Or Germline Variant Detection System

A next generation sequencing (NGS) oncology panel is a device used for the qualitative detection of germline or somatic variants in one or more cancer-related genes. The device is intended to be used on DNA or RNA isolated from human clinical specimens.

Product / regulatory recordCompanyPathwayDecision dateSource
Life Technologies CorporationPMA supplementNov 4, 2026FDA
xT CDxP210011/S006
Tempus AI, Inc.PMA supplementOct 23, 2026FDA
MI Cancer SeekP240010/S007
Caris Life SciencesPMA supplementOct 16, 2026FDA
Foundation Medicine, Inc.PMA supplementSep 18, 2026FDA
Guardant360 CDxP200010/S029
Guardant Health, Inc.PMA supplementSep 18, 2026FDA
FoundationOne CDxP170019/S069
Foundation Medicine, Inc.PMA supplementSep 16, 2026FDA
Life Technologies CorporationPMA supplementSep 9, 2026FDA
Guardant360 CDxP200010/S024
Guardant Health, Inc.PMA supplementSep 4, 2026FDA
Illumina, Inc.PMA supplementSep 4, 2026FDA
xT CDxP210011/S002
Tempus AI, Inc.PMA supplementSep 2, 2026FDA
Life Technologies CorporationPMA approvalJul 2, 2025FDA
Caris Life SciencesPMA approvalNov 5, 2024FDA
Illumina, Inc.PMA approvalAug 21, 2024FDA
xT CDxP210011
Tempus AI, Inc.PMA approvalApr 28, 2023FDA
Foundation Medicine, Inc.PMA approvalAug 26, 2020FDA
Guardant Health, Inc.PMA approvalAug 7, 2020FDA
Foundation Medicine, Inc.PMA approvalNov 30, 2017FDA
Source information

Follow the FDA links to view the original records.

All device categories